文献速递MDS 与骨髓增殖性肿瘤

真性红细胞增多症新治疗终点的探索:靶向克隆与炎症通路

Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways.
PubMed 文献 · Blood Adv · 2026-01-01

真性红细胞增多症(PV)的标准一线治疗放血和羟基脲(HU)未能充分解决克隆扩增和慢性炎症,而JAK2 V617F等位基因频率(VAF)和中性粒细胞与淋巴细胞比值(NLR)正成为指导治疗的有价值工具。Ropeginterferon alfa-2b可降低JAK2 VAF和NLR并改善无事件生存,而倾向性评分匹配显示HU对这些生物标志物影响有限。这些发现支持PV治疗向生物学指导转变,并提示炎症和JAK2 VAF可作为未来临床试验的替代终点。

要点

  • JAK2 VAF和NLR是有潜力的PV治疗指导生物标志物。
  • Ropeginterferon alfa-2b可降低JAK2 VAF和NLR并改善无事件生存。
  • HU对JAK2 VAF和NLR影响有限,疾病修饰潜力较弱。

核心结论

  • PV治疗应向生物学指导转变,炎症和JAK2 VAF可作为未来临床试验的替代终点。

研究设计与样本

  • 综述性文章,基于Low-PV和PROUD-PV/CONTINUATION-PV试验等证据进行论述。

主要发现

  • Ropeginterferon alfa-2b可降低JAK2 VAF和NLR,并改善无事件生存。
  • 欧洲协作低剂量阿司匹林试验的倾向性评分匹配显示,HU对JAK2 VAF和NLR影响有限。
  • Ruxolitinib对NLR动态变化的数据尚未发表,但其抗炎作用及对JAK2 VAF的抑制提示可能具有类似生物学活性。

临床怎么用

  • 可考虑将JAK2 VAF和NLR作为PV患者治疗决策的参考生物标志物。

局限性

  • Ruxolitinib对NLR动态变化的影响尚无已发表数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although phlebotomy and hydroxyurea (HU) are standard first-line therapies for polycythemia vera (PV), they do not adequately address clonal expansion and chronic inflammation, which are key drivers of thrombosis, myelofibrosis, and mortality. Biomarkers such as JAK2 V617F variant allele frequency (VAF) and the neutrophil-to-lymphocyte ratio (NLR) are emerging as valuable tools for guiding therapy. Ropeginterferon alfa-2b has been shown to reduce both JAK2 VAF and NLR, improving event-free survival, as demonstrated in the Low-PV and PROUD-PV/CONTINUATION-PV trials. In contrast, propensity score matching of the European Collaborative Low-Dose Aspirin trial showed that HU has a limited effect on these biomarkers, suggesting weaker disease-modifying potential. Although no data on NLR dynamics with ruxolitinib have been published, the anti-inflammatory effects of ruxolitinib and its suppression of JAK2 VAF suggest it may exert similar biological activity. These findings support a shift toward biology-guided treatment in PV, recognizing that inflammation and JAK2 VAF could serve as surrogate end points in future clinical trials.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Barbui T, Scandura JM. Toward new therapy end points in polycythemia vera: targeting clonal and inflammatory pathways. Blood Adv. 2026. PMID: 41370203. doi:10.1182/bloodadvances.2025018011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。